A prospective noninterventional real-world study of cabozantinib in pretreated patients with advanced renal cell carcinoma refractory to vascular endothelial growth factor-targeted therapy (CASSIOPE)
Michael Staehler,Umberto Basso,Jean-Christophe Eymard,Philippe Barthelemy,Pierre Bigot,Mathieu Laramas,Michael Rink,Cristina Suarez,Aline Guillot,Jens Bedke,Paul Hamberg,Rocco De Vivo,Pablo Gajate,Martín Lázaro-Quintela,Priti Rastogi,Valérie Perrot,Bryan Qvick,Pascale Dutailly,Elena Verzoni,Giuseppe Procopio
DOI: https://doi.org/10.1016/j.clgc.2024.102285
IF: 3.121
2024-12-02
Clinical Genitourinary Cancer
Abstract:Background There is a lack of published data on real-world cabozantinib use in patients with advanced renal cell carcinoma (aRCC) after prior vascular endothelial growth factor (VEGF)-targeted therapy. Methods CASSIOPE was a real-world, prospective, multicenter, noninterventional post-authorization safety study of cabozantinib in adult patients with aRCC in Europe following prior VEGF-targeted treatment (NCT03419572). Endpoints included cabozantinib utilization (dose modifications due to adverse events [AEs; primary endpoint], dose, dose modifications, and treatment duration), safety, effectiveness (progression-free survival [PFS], overall survival [OS], best overall response [BOR]), and healthcare resource utilization. Findings Full analysis set (FAS)/safety population comprised 679 patients; 433 of these initiated cabozantinib at 60 mg/day (recommended dose) (primary safety population). Median age (FAS) was 67 (range 29–93) years; most were male (73·0%), had clear-cell histology (85·7%), metastatic disease at cabozantinib initiation (97·8%), and prior nephrectomy (80·3%). In the primary safety population, 77·1% experienced dose modification owing to an AE. In the safety population, the median daily dose was 40·0 (range 7·8–60·0) mg/day and the median treatment duration was 7·8 (<0·1–15·2) months. Treatment-emergent and treatment-related AEs were experienced by 95·9% and 90·4% of patients, respectively. Median PFS (FAS) assessed by the local investigator using any method was 8·3 months, and 1-year OS rate was 74%. Approximately one-third of all patients had a BOR of partial response and 6 had a complete response. Interpretation Second- or later-line cabozantinib was effective and manageable in a real-world setting and had a safety profile consistent with previous studies. Micro-abstract CASSIOPE was a real-world study of cabozantinib use as a second-line or later line therapy for advanced renal cell carcinoma after prior VEGF-targeted therapy. Of 679 patients prospectively enrolled in Europe, second-line or later line cabozantinib use was shown to be effective and manageable in a real-world setting and had a safety profile consistent with previous studies.
oncology,urology & nephrology